Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

Athyros Vasilios G.; Katsiki Niki; Karagiannis Asterios

首页> 外文期刊>Current vascular pharmacology >Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

【24h】

Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

机译：胰高血糖素样肽1（GLP1）激动剂或钠葡萄糖共转运蛋白2（SGLT2）抑制剂能否改善患有或不患有糖尿病的人的非酒精性脂肪性肝炎？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Current vascular pharmacology》 |2016年第6期|共4页
作者
Athyros Vasilios G.; Katsiki Niki; Karagiannis Asterios;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? [J] . Athyros Vasilios G., Katsiki Niki, Karagiannis Asterios Current vascular pharmacology . 2016,第6期

机译：胰高血糖素样肽1（GLP1）激动剂或钠葡萄糖共转运蛋白2（SGLT2）抑制剂能否改善患有或不患有糖尿病的人的非酒精性脂肪性肝炎？
2. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors [J] . Ohki Takamasa, Isogawa Akihiro, Toda Nobuo, Clinical drug investigation . 2016,第4期

机译：依格列净，一种钠-葡萄糖共转运蛋白2抑制剂，对二型糖尿病非酒精性脂肪性肝病患者的二线治疗无效，这些患者对包括胰高血糖素样肽-1类似物在内的基于肠促胰岛素的疗法无反应和Depteptidyl Peptidase-4抑制剂
3. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [J] . Gy?rgy Jermendy, Zoltán Kiss, Gy?rgy Rokszin, Diabetes therapy . 2018,第5期

机译：在2型糖尿病患者中持续使用新型抗糖尿病药物（二肽基肽酶4抑制剂，钠葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂）进行的全国性队列研究
4. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018

机译：在2型糖尿病患者中持续使用新型抗糖尿病药物（二肽基肽酶4抑制剂钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂）进行的全国性队列研究
5. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018

机译：持续治疗新型抗糖尿病药物（二肽基肽酶-4抑制剂，钠葡萄糖共转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂），其患有2型糖尿病的人：全国范围内的队列研究

Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

著录项

相似文献

相关主题

期刊订阅